IOVA vs RLAY: stock comparison and AI forecast
Iovance Biotherapeutics, Inc. (IOVA) and Relay Therapeutics, Inc. (RLAY) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IOVA Iovance Biotherapeutics, Inc.
- Price
- $8.02 +108.3% · 6M
- Market Cap
- $3.63B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
RLAY Relay Therapeutics, Inc.
- Price
- $18.35 +41.6% · 6M
- Market Cap
- $4.02B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- RLAY is 1.1 times larger than IOVA by market capitalization ($4.02B against $3.63B).
- Over the last six months IOVA returned +108.3% and RLAY +41.6%.
- IOVA turns -89.1% of its revenue into net income, against -2763.9% for RLAY.
- IOVA carries 0.24 times debt per unit of equity, against 0.09 times for RLAY.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IOVA | RLAY |
|---|---|---|
| Market Cap | $3.63B | $4.02B |
| P/B Ratio | 4.94x | 4.52x |
| EPS | $-0.84 | $-1.61 |
| Book Value/Share | $1.62 | $4.06 |
| Revenue/Share | $0.72 | $0.05 |
| FCF/Share | $-0.65 | – |
Profitability & Margins
| Metric | IOVA | RLAY |
|---|---|---|
| ROE | -39.3% | -32.1% |
| ROA | -31.6% | -29.6% |
| ROIC | -37.3% | -33.9% |
| Gross Margin | 53.0% | – |
| Operating Margin | -92.7% | -2999.7% |
| Net Margin | -89.1% | -2763.9% |
| EBT Margin | -90.4% | -2999.7% |
| Tax Rate | 1.4% | – |
Financial Health
| Metric | IOVA | RLAY |
|---|---|---|
| Current Ratio | 4.35x | 18.27x |
| Quick Ratio | 3.82x | – |
| D/E Ratio | 0.24x | 0.09x |
| Financial Leverage | 1.24x | 1.09x |
| Interest Coverage | 31.2x | – |
| Working Capital | $357M | $877M |
Cash Flow
| Metric | IOVA | RLAY |
|---|---|---|
| Operating Cash Flow | -$264M | -$212M |
| Free Cash Flow | -$296M | – |
| Capital Spending | -$32M | – |
| FCF/Sales | -91.2% | – |
| CapEx/Sales | 9.9% | – |
Operational Efficiency
| Metric | IOVA | RLAY |
|---|---|---|
| Asset Turnover | 0.35x | 0.01x |
| Receivables Turnover | 3.2x | – |
| Inventory Turnover | 2.8x | – |
| Fixed Assets Turnover | 2.5x | 12.0x |
| Days Sales Outstanding | 115 days | – |
| Days Inventory | 133 days | – |
| Payables Period | 63 days | – |
| Cash Conversion Cycle | 185 days | – |
Income Statement
| Metric | IOVA | RLAY |
|---|---|---|
| Total Revenue | $325M | $10M |
| Operating Income | -$301M | -$310M |
| Net Income | -$290M | -$286M |
| R&D Expense | $265M | $271M |
| Cost of Goods Sold | $153M | – |
Dividend & Shareholder Information
| Metric | IOVA | RLAY |
|---|---|---|
| Shares Outstanding | 453M | 219M |
IOVA vs RLAY: stock comparison and AI forecast
Which is bigger, IOVA or RLAY?
RLAY is 1.1 times larger than IOVA by market capitalization ($4.02B against $3.63B).
Which stock performed better over the last six months, IOVA or RLAY?
Over the last six months IOVA returned +108.3% and RLAY +41.6%.
Which one does Intratio's AI model rank higher, IOVA or RLAY?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.